title: Cocktails for cancer with a measure of immunotherapy.
authors.forename: Heidi
authors.initials: H
authors.lastname: Ledford
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019013:CD40 Antigens / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D044127:Epigenesis, Genetic / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000628:therapy; D000077594:Nivolumab; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000401:mortality; D017741:Survivors; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines; D000074324:Ipilimumab; D000077594:Nivolumab